BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

...Preclin Kinases/Transcription factors p38 mitogen-activated protein kinase (p38 MAPK; MAPK14) Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) / EIP Pharma LLC...
BioCentury | May 18, 2018
Financial News

EIP gets $20.5M to develop AD candidate

...CNS company EIP Pharma LLC (Cambridge, Mass.) raised $20.5 million on May 16 in a series B round...
...expressed in the microglia and astrocytes where it regulates inflammation. EIP Pharma LLC, Cambridge, Mass. Elizabeth S. Eaton neflamapimod (VX-745) EIP Pharma LLC p38...
BioCentury | May 16, 2018
Financial News

EIP gets $20.5M to develop AD candidate

...CNS company EIP Pharma LLC (Cambridge, Mass.) raised $20.5 million in a series B round led by new...
...MAPK14), which is expressed in the microglia and astrocytes where it regulates inflammation. Elizabeth S. Eaton neflamapimod (VX-745) EIP Pharma LLC p38...
BioCentury | Mar 23, 2017
Finance

Biology on the mind

...previously tested by Astellas to treat pain, but Cardeus is exploring other indications including neurodegeneration. EIP Pharma LLC...
...Therapeutics Ltd. London, U.K. Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Cardeus Pharmaceuticals Inc., Menlo Park, Calif. EIP Pharma LLC...
BioCentury | Jan 20, 2017
Clinical News

Neflamapimod: Ph IIa Study 303 data

...mg dose of neflamapimod in a Phase IIb trial. The company licensed neflamapimod from Vertex. EIP Pharma LLC...
...Learning Test-Revised (HLVT-R), Mini-Mental State Examination (MMSE) and safety Status: Phase IIa data Milestone: NA Julian Zhu neflamapimod VX-745 EIP Pharma LLC Vertex...
BioCentury | Jan 20, 2017
Clinical News

Neflamapimod: Ph IIa Study 302 data

...mg dose of neflamapimod in a Phase IIb trial. The company licensed neflamapimod from Vertex. EIP Pharma LLC...
...Memory Scale (WMS), Mini-Mental State Examination (MMSE) and safety Status: Phase IIa data Milestone: NA Julian Zhu neflamapimod VX-745 EIP Pharma LLC Vertex...
BioCentury | Dec 17, 2016
Product Development

Not dead yet

...two from AC Immune S.A. , for which Phase I data are expected in 1H17. EIP Pharma LLC...
...but not for AD. Inflammation is believed to be a downstream affect of plaque formation. EIP Pharma...
...St. Louis, Mo. Columbia University, New York, N.Y. Columbia University Medical Center, New York, N.Y. EIP Pharma LLC...
Items per page:
1 - 7 of 7
BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

...Preclin Kinases/Transcription factors p38 mitogen-activated protein kinase (p38 MAPK; MAPK14) Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) / EIP Pharma LLC...
BioCentury | May 18, 2018
Financial News

EIP gets $20.5M to develop AD candidate

...CNS company EIP Pharma LLC (Cambridge, Mass.) raised $20.5 million on May 16 in a series B round...
...expressed in the microglia and astrocytes where it regulates inflammation. EIP Pharma LLC, Cambridge, Mass. Elizabeth S. Eaton neflamapimod (VX-745) EIP Pharma LLC p38...
BioCentury | May 16, 2018
Financial News

EIP gets $20.5M to develop AD candidate

...CNS company EIP Pharma LLC (Cambridge, Mass.) raised $20.5 million in a series B round led by new...
...MAPK14), which is expressed in the microglia and astrocytes where it regulates inflammation. Elizabeth S. Eaton neflamapimod (VX-745) EIP Pharma LLC p38...
BioCentury | Mar 23, 2017
Finance

Biology on the mind

...previously tested by Astellas to treat pain, but Cardeus is exploring other indications including neurodegeneration. EIP Pharma LLC...
...Therapeutics Ltd. London, U.K. Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Cardeus Pharmaceuticals Inc., Menlo Park, Calif. EIP Pharma LLC...
BioCentury | Jan 20, 2017
Clinical News

Neflamapimod: Ph IIa Study 303 data

...mg dose of neflamapimod in a Phase IIb trial. The company licensed neflamapimod from Vertex. EIP Pharma LLC...
...Learning Test-Revised (HLVT-R), Mini-Mental State Examination (MMSE) and safety Status: Phase IIa data Milestone: NA Julian Zhu neflamapimod VX-745 EIP Pharma LLC Vertex...
BioCentury | Jan 20, 2017
Clinical News

Neflamapimod: Ph IIa Study 302 data

...mg dose of neflamapimod in a Phase IIb trial. The company licensed neflamapimod from Vertex. EIP Pharma LLC...
...Memory Scale (WMS), Mini-Mental State Examination (MMSE) and safety Status: Phase IIa data Milestone: NA Julian Zhu neflamapimod VX-745 EIP Pharma LLC Vertex...
BioCentury | Dec 17, 2016
Product Development

Not dead yet

...two from AC Immune S.A. , for which Phase I data are expected in 1H17. EIP Pharma LLC...
...but not for AD. Inflammation is believed to be a downstream affect of plaque formation. EIP Pharma...
...St. Louis, Mo. Columbia University, New York, N.Y. Columbia University Medical Center, New York, N.Y. EIP Pharma LLC...
Items per page:
1 - 7 of 7